CLL/SLL

How will the results of the phase III ASCEND trial change treatment practice of R/R CLL?

L:

During ICML 2019 in Lugano, Switzerland, the Lymphoma Hub were pleased to speak to Paolo Ghia from University Vita-Salute San Raffaele, Milan, IT, about how the results of the phase III ASCEND trial might change treatment practice of relapsed/refractory chronic lymphocytic leukemia (CLL).

Paolo Ghia discusses how the multicenter, international study compared a classic chemotherapy treatment with a chemotherapy-free treatment, and with a novel BTK inhibitor. He mentions how, for the first time, two chemotherapy-free treatments were compared.

Download this article:

You can now download this article in Adobe PDF® format.

Download as PDF